Alzheimer's Disease
Conditions
Keywords
Alzheimer's Disease, Octohydroaminoacridine Succinate
Brief summary
The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.
Detailed description
The purpose of this study is a preliminary assessment of the Octohydroaminoacridine Succinate tablets in the treatment of mild to moderate Alzheimer's disease and explore the efficacy and safety of the best dose. The 288 patients were randomly assigned to four groups: high dose (4mg / time), moderate dose (2mg / time), low dose (1mg / time) and the placebo group, including four weeks of the trial screening period following 16 weeks double-blind treatment.
Interventions
DRUGOctohydroaminoacridine Succinate Tablets
1mg, tid
DRUGOctohydroaminoacridine succinate Tablets
1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
DRUGPlacebo
0mg, tid
Sponsors
Beijing Bionovo Medicine Development Co., Ltd.
Changchun Huayang High-tech Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosis of probable AD based on DSM-IV and the NINCDS-ADRDA criteria. 2. Male/female patient aged between 50 and 85. 3. mild to moderate probable AD ：Middle school or above: 11 ≤MMSE ≤ 25, elementary school: 8 ≤ MMSE ≤ 20, illiteracy: 5 ≤ MMSE ≤ 16. 4. CT or MRI scan excluding another structural brain disease in one year. 5. Neurologic examination no significant abnormalities. 6. Hachinski Ischemic Score \< 4；Hamilton Depression Scale ≤10. Able to complete the test procedure, audio-visual and physical ability to act to complete the neuropsychological measure. 7. Stable chaperone, more than 2 hours a day together with the patient or accumulated fewer than 14 hours per week. 8. Informed consent of the patient (or legal representative) and of the caregiver agreeing to take part in the study.
Exclusion criteria
1. Proven or clinically suspected other type of dementia such as vascular dementia, Lewy body dementia, Parkinson's disease, frontotemporal dementia, g - Jakob disease (spastic pseudo-sclerosis), normal pressure hydrocephalus etc. 2. Sudden onset of early dementia or with gait disorders, seizures and behavioral changes. 3. Clinical manifestations of focal neurological signs (hemiparesis, sensory loss, visual field defect) or early extrapyramidal tract signs. 4. History of cerebrovascular disease and stroke. 5. Serious lack of folic acid and VitB12, syphilis antibody positive or thyroid dysfunction. 6. Mechanical intestinal obstruction patient ,Resting pulse less than 60,Severe liver or renal disease. 7. Patients with mechanical intestinal obstruction. 8. History of bone marrow transplantation.Mental illness, such as severe depression. 9. Cognitive damage caused by alcohol or drug abuse. Disable to correctly evaluate the cognitive function. 10. Critical condition, disable to make the exact evaluation of the efficacy and safety of new drug. 11. Use of any agent for the treatment of dementia within 4 weeks of randomization. 12. Be sensitive to ACHEI. 13. Be sensitive to two or more foods/drugs. 14. Use of another investigational agent within one months of screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alzheimer's Disease Assessment Scale - Cognitive Subscale | 20weeks |
Secondary
| Measure | Time frame |
|---|---|
| Clinician's Interview Based Impression of Change, plus caregiver input | 20weeks |
| Activities of Daily Living:Activities of Daily Living Scale（ADL) | 20weeks |
| Mental behavior: neuropsychiatric questionnaire (NPI) | 20weeks |
Countries
China
Contacts
Primary ContactHuafang Li, MD
Outcome results
None listed